Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-41. Cancelled.

Claim 42. (Currently amended) A method ~~for~~ of treating a disease, disorder, or condition by reducing the levels of Aβ peptide in a mammalian brain, comprising administering a therapeutically effective amount of a soluble Nogo receptor-1 polypeptide to a patient in need of reduced levels of Aβ peptide, wherein said soluble Nogo receptor-1 polypeptide comprises an NT domain, eight leucine-rich repeats, and an LRRCT (leucine-rich-repeat domain C-terminal of the eight leucine-rich repeats) domain.

Claim 43. (Cancelled)

Claim 44. (Currently amended) The method of claim [[43]] 42, wherein said disease, disorder or condition is Alzheimer's disease.

Claim 45. (Previously presented) The method of claim 42, wherein the soluble Nogo receptor-1 polypeptide is administered by bolus injection or chronic infusion.

Claim 46. (Previously presented) The method of claim 45, wherein the soluble Nogo receptor-1 polypeptide is administered directly into the central nervous system.

Claim 47. (Currently amended) The method of claim 42, wherein the soluble Nogo receptor-1 (NgR1) polypeptide is a soluble form of a mammalian NgR1.

Claim 48. (Withdrawn) The method of claim 47, wherein the soluble form of a mammalian NgR1 comprises a peptide selected from the group consisting of:

(a) amino acids 26 to 310 of human NgR1 (SEQ ID NO:3) with up to ten conservative amino acid substitutions;

(b) amino acids 26 to 344 of human NgR1 (SEQ ID NO:4) with up to ten conservative amino acid substitutions;

(c) amino acids 27 to 310 of rat NgR1 (SEQ ID NO:5) with up to ten conservative amino acid substitutions; and

(d) amino acids 27 to 344 of rat NgR1 (SEQ ID NO:6) with up to ten conservative amino acid substitutions.

Claim 49. (Currently amended) The method of claim [[48]] 47, wherein the soluble form of a mammalian NgR1 comprises a peptide selected from the group consisting of:

(a) amino acids 26 to 310 of human NgR1 (SEQ ID NO:3);

(b) amino acids 26 to 344 of human NgR1 (SEQ ID NO:4);

(c) amino acids 27 to 310 of rat NgR1 (SEQ ID NO:5); and

(d) amino acids 27 to 344 of rat NgR1 (SEQ ID NO:6).

Claim 50. (Currently amended) The method of claim 47, wherein the soluble form of a mammalian NgR1 further comprises ~~a fusion moiety~~ an immunoglobulin constant domain.

Claim 51. (Previously presented) The method of claim 42, wherein the therapeutically effective amount is from 0.001 mg/kg to 10 mg/kg of soluble Nogo receptor-1 polypeptide.

Claim 52. (Currently amended) A method of treating a disease, disorder or condition associated with plaques of Aβ peptide in a mammalian brain, comprising administering a therapeutically effective amount of a soluble Nogo receptor-1 polypeptide to a patient in need of reduction of plaque deposits, wherein said soluble Nogo receptor-1 polypeptide comprises an NT domain, eight leucine-rich repeats, and an LRRCT (leucine-rich-repeat domain C-terminal of the eight leucine-rich repeats) domain and wherein said polypeptide reduces plaque deposits.

Claim 53. (Previously presented) The method of claim 52, wherein said disease, disorder or condition is Alzheimer's Disease.

Claim 54. (Previously presented) The method of claim 52, wherein the soluble Nogo receptor-1 polypeptide is administered by bolus injection or chronic infusion.

Claim 55. (Previously presented) The method of claim 54, wherein the soluble Nogo receptor-1 polypeptide is administered directly into the central nervous system.

Claim 56. (Currently amended) The method of claim 52, wherein the soluble Nogo receptor-1 (NgR1) polypeptide comprises a soluble form of a mammalian NgR1.

Claim 57. (Withdrawn) The method of claim 56, wherein the soluble form of a mammalian NgR1 comprises a peptide selected from the group consisting of:

(a) amino acids 26 to 310 of human NgR1 (SEQ ID NO:3) with up to ten conservative amino acid substitutions;

(b) amino acids 26 to 344 of human NgR1 (SEQ ID NO:4) with up to ten conservative amino acid substitutions;

(c) amino acids 27 to 310 of rat NgR1 (SEQ ID NO:5) with up to ten conservative amino acid substitutions; and

(d) amino acids 27 to 344 of rat NgR1 (SEQ ID NO:6) with up to ten conservative amino acid substitutions.

Claim 58. (Currently amended) The method of claim [[57]] 56, wherein the soluble form of a mammalian NgR1 comprises a peptide selected from the group consisting of:

(a) amino acids 26 to 310 of human NgR1 (SEQ ID NO:3);

(b) amino acids 26 to 344 of human NgR1 (SEQ ID NO:4);

(c) amino acids 27 to 310 of rat NgR1 (SEQ ID NO:5); and

(d) amino acids 27 to 344 of rat NgR1 (SEQ ID NO:6).

Claim 59. (Currently amended) The method of claim 56, wherein the soluble form of a mammalian NgR1 further comprises ~~a fusion moiety~~ an immunoglobulin constant domain.

Claim 60. (Previously presented) The method of claim 52, wherein the therapeutically effective amount is from 0.001 mg/kg to 10 mg/kg of soluble Nogo receptor-1 polypeptide.

Claim 61. (Cancelled)